{"id":10252,"date":"2025-12-08T18:55:57","date_gmt":"2025-12-08T14:55:57","guid":{"rendered":"https:\/\/medscriptum.org\/?p=10252"},"modified":"2025-12-08T18:55:58","modified_gmt":"2025-12-08T14:55:58","slug":"scientists-find-a-safe-and-effective-way-to-deliver-chemotherapy-to-the-brain-to-treat-glioblastoma","status":"publish","type":"post","link":"https:\/\/medscriptum.org\/en\/scientists-find-a-safe-and-effective-way-to-deliver-chemotherapy-to-the-brain-to-treat-glioblastoma\/","title":{"rendered":"Scientists Find a Safe and Effective Way to Deliver Chemotherapy to the Brain to Treat Glioblastoma"},"content":{"rendered":"<p data-path-to-node=\"1\">Scientists may have found a new way to treat glioblastoma, a particularly aggressive brain tumor. Researchers at Northwestern University&#8217;s Feinberg School of Medicine conducted a Phase I clinical trial, the results of which were published in <i>The Lancet Oncology<\/i> medical journal.<\/p>\n<p data-path-to-node=\"2\">The study was conducted on 17 patients with recurrent glioblastoma and involved the use of SonoCloud-9\u00ae, an implantable ultrasound device.<\/p>\n<p data-path-to-node=\"3\">This new approach to treating glioblastoma uses the SonoCloud-9\u00ae implantable ultrasound device to temporarily disrupt the brain\u2019s protective barrier, the blood-brain barrier (BBB). The process begins with the injection of microbubbles into the patient&#8217;s bloodstream. Upon activation of the ultrasound, these microbubbles vibrate, mechanically disrupting the tight junctions of the BBB cells near the tumor. Through this breached barrier, the chemotherapy drug, albumin-bound paclitaxel, easily reaches the tumor tissue in high concentration, significantly increasing the effectiveness of the treatment.<\/p>\n<p data-path-to-node=\"4\">The treatment outcomes showed a significant increase in efficacy, as a subgroup of patients demonstrated that the method used increased the concentration of chemotherapy crossing the blood-brain barrier (BBB) and reaching the area surrounding the tumor by <b>4 to 6 times<\/b>.<\/p>\n<p data-path-to-node=\"5\">The method proved to be safe and well-tolerated by the patients. This fact was further confirmed as each participant received up to six cycles of chemotherapy and ultrasound device activation, indicating the feasibility of successful repeated delivery.<\/p>\n<p data-path-to-node=\"6\">Furthermore, the use of SonoCloud-9\u00ae makes it possible to open the BBB over a large region of the brain, which in turn significantly expands the area of chemotherapy delivery and the potential effectiveness of the treatment.<\/p>\n<p data-path-to-node=\"7\">&#8220;The technology is a potentially huge step forward for glioblastoma patients,&#8221; said Dr. Sonabend. &#8220;Today&#8217;s standard chemotherapy, temozolomide, is weak. In the past, directly injecting paclitaxel or carboplatin into the brain was associated with toxicity. In our study, using the SonoCloud-9 showed promise for safe delivery.&#8221;<\/p>\n<p data-path-to-node=\"7\"><a href=\"https:\/\/www.fusfoundation.org\/posts\/cartheras-sonocloud-9-device-facilitates-delivery-of-chemotherapy-to-glioblastomas\/#:~:text=The%20results%20from%20Northwestern%20University&#039;s,but%20is%20a%20weak%20drug\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">fusfoundation<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Scientists may have found a new way to treat glioblastoma, a particularly aggressive brain tumor. Researchers at Northwestern University&#8217;s Feinberg School of Medicine conducted a Phase I clinical trial, the results of which were published in The Lancet Oncology medical journal. The study was conducted on 17 patients with recurrent glioblastoma and involved the use [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":10251,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1594,1587,1657,1659],"tags":[1923,3303],"class_list":["post-10252","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","category-research","category-science","category-technologies","tag-chemotherapy","tag-glioblastoma"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/10252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=10252"}],"version-history":[{"count":1,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/10252\/revisions"}],"predecessor-version":[{"id":10257,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/10252\/revisions\/10257"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/10251"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=10252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=10252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=10252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}